Hjem
Bjørn Tore Gjertsens bilde
Foto:
CCBIO/Ingvild Festervoll Melien

Bjørn Tore Gjertsen

Professor, Professor i blodsykdommer
  • E-postBjorn.Gjertsen@uib.no
  • Telefon+47 55 97 29 68+47 415 66 248
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
  • Postadresse
    Postboks 7804
    5020 Bergen

Bjørn Tore Gjertsen, MD, PhD. is Professor of Hematology from 2007 at Department of Clinical Science at the University of Bergen, working as Research Chief and Consultant Hematologist at Helse Bergen Health Trust, developing early phase clinical trials at Haukeland University Hospital. In 2016 Gjertsen was appointed co-director for Centre for Cancer Biomarkers (CCBIO) Norwegian Centre of Excellence, University of Bergen. His major research interest is development of targeted therapy and accompanying diagnostics in the aggressive blood cancer acute myeloid leukemia. His laboratory is working on intracellular signal transduction and its regulation of the tumor suppressor protein p53. Single cell signaling and immune profiling by multiplexing mass cytometry has been developed for monitoring of immuno- and signaling-directed therapy and is currently used for therapy development of various cancers and myeloid leukemias.

Utvalgte publikasjoner
  • Reikvam, Håkon; Hovland, Randi; Forthun, Rakel Brendsdal; Erdal, Sigrid; Gjertsen, Bjørn Tore; Fredly, Hanne Kristin; Bruserud, Øystein. 2017. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer. 17:630: 1-13. doi: 10.1186/s12885-017-3620-y
  • Karjalainen, Riikka; Pemovska, Tea; Popa, Mihaela Lucia; Liu, Minxia; Javarappa, Komal K.; Majumder, Muntasir Mamun; Yadav, Bhagwan; Tamborero, David; Tang, Jing; Bychkov, Dmitrii; Kontro, Mika; Parsons, Alun; Suvela, Minna; Mayoral Safont, Mireia; Porkka, Kimmo; Aittokallio, Tero; Kallioniemi, Olli; McCormack, Emmet; Gjertsen, Bjørn Tore; Wennerberg, Krister; Knowles, Jonathan; Heckman, Caroline Akemi. 2017. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood. 130: 789-802. doi: 10.1182/blood-2016-02-699363
  • Gullaksen, Stein-Erik; Skavland, Jørn; Gavasso, Sonia; Tosevski, Vinko; Warzocha, Krzysztof; Dumrese, Claudia; Ferrant, Augustin; Gedde-Dahl, Thobias; Hellmann, Andrzej; Janssen, Jeroen; Labar, Boris; Lang, Alois; Majeed, Mohammed Waleed; Mihaylov, Georgi; Stentoft, Jesper; Stenke, Leif; Thaler, Josef; Thielen, Noortje; Verhoef, Gregor; Voglova, Jaroslava; Ossenkoppele, Gert; Hochhaus, Andreas; Hjorth-Hansen, Henrik; Mustjoki, Satu; Sopper, Sieghart; Giles, Francis; Porkka, Kimmo; Wolf, Dominik; Gjertsen, Bjørn Tore. 2017. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica. 102: 1361-1367. doi: 10.3324/haematol.2017.167080
  • Rajala, Hanna L.M.; El Missiry, Mohamed; Ruusila, Anniina; Koskenvesa, Perttu; Brümmendorf, Tim H.; Gjertsen, Bjørn Tore; Janssen, Jeroen; Lotfi, Kourosh; Markevärn, Berit; Olsson-Strömberg, Ulla; Stenke, Leif; Stentoft, Jesper; Richter, Johan; Hjorth-Hansen, Henrik; Kreutzman, Anna; Mustjoki, Satu. 2017. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 143: 1543-1554. doi: 10.1007/s00432-017-2378-6
  • Omsland, Maria; Bruserud, Øystein; Gjertsen, Bjørn Tore; Andresen, Vibeke. 2017. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-KB inhibition in acute myeloid leukemia (AML). OncoTarget. 8: 7946-7963. doi: 10.18632/oncotarget.13853
  • Sopper, Sieghart; Mustjoki, Satu; White, Deborah; Hughes, Timothy; Valent, Peter; Burchert, Andreas; Gjertsen, Bjørn Tore; Gastl, Günther; Baldauf, Matthias; Trajanoski, Zlatko; Giles, Frank; Hochhaus, Andreas; Ernst, Thomas; Schenk, Thomas; Janssen, Jeroen J.W.M.; Ossenkoppele, Gert J.; Porkka, Kimmo; Wolf, Dominik. 2017. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. Journal of Clinical Oncology. 35: 175-184. doi: 10.1200/JCO.2016.67.0893
  • Kotopoulis, Spiros; Stigen, Endre; Popa, Mihaela Lucia; Mayoral Safont, Mireia; Healey, Andrew; Kvåle, Svein; Sontum, Per; Gjertsen, Bjørn Tore; Gilja, Odd Helge; McCormack, Emmet. 2017. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. Journal of Controlled Release. 245: 70-80. doi: 10.1016/j.jconrel.2016.11.019
  • Kontro, Mika; Kumar, Anil; Majumder, Muntasir Mamun; Eldfors, Samuli; Parsons, Alun; Pemovska, Tea; Saarela, Janna; Yadav, Bhagwan; Malani, Disha; Fløisand, Yngvar; Höglund, Martin; Remes, Kari Juhani; Gjertsen, Bjørn Tore; Kallioniemi, Olli; Wennerberg, Krister; Heckman, Caroline Akemi; Porkka, Kimmo. 2017. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. Leukemia. 31: 301-309. doi: 10.1038/leu.2016.222
  • Andresen, Vibeke; Erikstein, Bjarte Skoe; Mukherjee, Herschel; Sulen, Andre; Popa, Mihaela Lucia; Sørnes, Steinar; Reikvam, Håkon; Chan, Kok-Ping; Hovland, Randi; McCormack, Emmet; Bruserud, Øystein; Myers, Andrew G.; Gjertsen, Bjørn Tore. 2016. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death & Disease. 7:e2497: 1-14. doi: 10.1038/cddis.2016.392
  • Thielen, Noortje; Richter, Johan; Baldauf, Matthias; Barbany, Gisela; Fioretos, Thoas; Giles, Francis; Gjertsen, Bjørn Tore; Hochhaus, Andreas; Schuurhuis, Gerrit Jan; Sopper, Sieghart; Stenke, Leif; Thunberg, Sarah; Wolf, Dominik; Ossenkoppele, Gert; Porkka, Kimmo; Janssen, Jeroen; Mustjoki, Satu. 2016. Leukemic stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy. Clinical Cancer Research. 22: 4030-4038. doi: 10.1158/1078-0432.CCR-15-2791
  • Sulen, Andre; Gjertsen, Bjørn Tore. 2016. Leukocyte p38 and p53 proteins after environmental exposure; variation, associations and applicability. Universitetet i Bergen.
  • Helland, Øystein; Popa, Mihaela Lucia; Bischof, Katharina; Gjertsen, Bjørn Tore; McCormack, Emmet; Bjørge, Line. 2016. The HDACi panobinostat shows growth inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer. PLOS ONE. 11:e0158208. doi: 10.1371/journal.pone.0158208
  • Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen; Hoem, Dag; Schjøtt, Jan; Gjertsen, Bjørn Tore; Biermann, Martin; Molven, Anders; Sorbye, Halfdan; McCormack, Emmet; Postema, Michiel; Gilja, Odd Helge. 2016. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release. 243: 172-181. doi: 10.1016/j.jconrel.2016.10.007
  • Sulen, Andre; Gullaksen, Stein-Erik; Bader, Lucius; McClymont, David; Skavland, Jørn; Gavasso, Sonia; Gjertsen, Bjørn Tore. 2016. Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells. Pharmacological Research. 113: 216-227. doi: 10.1016/j.phrs.2016.08.018
  • Hjorth-Hansen, Henrik; Stentoft, Jesper; Richter, Johan; Koskenvesa, Perttu; Höglund, Martin; Dreimane, Arta; Porkka, Kimmo; Gedde-Dahl, Thobias; Gjertsen, Bjørn Tore; Gruber, Franz; Stenke, Leif; Myhr-Eriksson, Kristina; Markevärn, Berit; Lübking, Anna; Vestergaard, Hanne; Udby, Lene; Bjerrum, Ole Weis; Persson, Inger; Mustjoki, Satu; Olsson-Strömberg, Ulla. 2016. Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 30: 1853-1860. doi: 10.1038/leu.2016.121
  • Sulen, Andre; Lygre, Stein Håkon Låstad; Hjelle, Sigrun Margrethe; Hollund, Bjørg Eli; Gjertsen, Bjørn Tore. 2016. Elevated monocyte phosphorylated p38 in nearby employees after a chemical explosion. Scientific Reports. 6:29060. doi: 10.1038/srep29060
  • Leitch, Calum; Osdal, Tereza; Andresen, Vibeke; Molland, Maren Kristine Butler; Kristiansen, Silje Elisabeth; Nguyen, Nhi Xuan; Bruserud, Øystein; Gjertsen, Bjørn Tore; McCormack, Emmet. 2016. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. OncoTarget. 7: 8105-8118. doi: 10.18632/oncotarget.6991
  • Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen; Hoem, Dag; Schjøtt, Jan; Gjertsen, Bjørn Tore; Biermann, Martin; Molven, Anders; Sorbye, Halfdan; McCormack, Emmet; Postema, Michiel; Gilja, Odd Helge. 2016. Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. Journal of Clinical Oncology. 34:e15703.
  • Gavasso, Sonia; Gullaksen, Stein-Erik; Skavland, Jørn; Gjertsen, Bjørn Tore. 2016. Single-cell proteomics: Potential implications for cancer diagnostics. Expert Review of Molecular Diagnostics. 16: 579-589. doi: 10.1586/14737159.2016.1156531
  • Kotopoulis, Spiros; Dimcevski, Georg Gjorgji; McCormack, Emmet; Postema, Michiel; Gjertsen, Bjørn Tore; Gilja, Odd Helge. 2016. Ultrasound- and microbubble-enhanced chemotherapy for treating pancreatic cancer: a phase I clinical trial. Journal of the Acoustical Society of America. 139: 2092-2092. doi: 10.1121/1.4950209
  • Engen, Caroline Benedicte Nitter; Hajjar, Ehsan; Gjertsen, Bjørn Tore. 2016. Development of personalized molecular therapy for acute myeloid leukemia. Current Pharmaceutical Biotechnology. 17: 20-29. doi: 10.2174/1389201016666150930115024
  • Vis forfatter(e) 2021. p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy. Cells.
  • Vis forfatter(e) 2021. Temperature-dependent autoactivation associated with clinical variability of PDGFRB Asn666 substitutions. Human Molecular Genetics. 72-77.
  • Vis forfatter(e) 2021. Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis. Molecular Oncology. 2285-2299.
  • Vis forfatter(e) 2021. Phenotypic Characterization by Mass Cytometry of the Microenvironment in Ovarian Cancer and Impact of Tumor Dissociation Methods. Cancers. 1-18.
  • Vis forfatter(e) 2021. Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study. European Journal of Haematology. 1-7.
  • Vis forfatter(e) 2021. Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System . Cancers.
  • Vis forfatter(e) 2021. FLT3-ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation. Molecular Oncology. 2300-2317.
  • Vis forfatter(e) 2021. Colony stimulating factor 1 receptor in acute myeloid leukemia. Frontiers in Oncology. 1-12.
  • Vis forfatter(e) 2021. Cerebrospinal fluid proteome shows disrupted neuronal development in multiple sclerosis. Scientific Reports.
  • Vis forfatter(e) 2020. Ultrasound‐ and microbubble‐assisted gemcitabine delivery to pancreatic cancer cells. Pharmaceutics. 1-15.
  • Vis forfatter(e) 2020. Synthesis of N-aryl- and N-alkyl-substituted imidazolium silver complexes: Cytotoxic screening by using human cell lines modelling acute myeloid leukaemia. ChemMedChem. 1509-1514.
  • Vis forfatter(e) 2020. Single cell detection of the p53 protein by mass cytometry. Cancers. 1-15.
  • Vis forfatter(e) 2020. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 708-720.
  • Vis forfatter(e) 2020. Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition. Leukemia. 1-11.
  • Vis forfatter(e) 2020. Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. Haematologica. 1527-1538.
  • Vis forfatter(e) 2020. Low-Intensity Sonoporation-Induced Intracellular Signalling of Pancreatic Cancer Cells, Fibroblasts and Endothelial Cells. Pharmaceutics. 1-17.
  • Vis forfatter(e) 2020. Hit to leads with cytotoxic effect in leukemic cells: Total synthesis intermediates as a molecule treasure chest. ChemMedChem. 862-870.
  • Vis forfatter(e) 2020. Exploring the boundaries of precision haemato-oncology – The case of FLT3 length mutated acute myeloid leukaemia.
  • Vis forfatter(e) 2020. Early Response to the Plant Toxin Stenodactylin in Acute Myeloid Leukemia Cells Involves Inflammatory and Apoptotic Signaling. Frontiers in Pharmacology.
  • Vis forfatter(e) 2020. CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. EBioMedicine. 1-13.
  • Vis forfatter(e) 2020. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia.
  • Vis forfatter(e) 2020. A microfluidic device for differential capture of heterogeneous rare tumor cells with epithelial and mesenchymal phenotypes. Analytica Chimica Acta. 1-11.
  • Vis forfatter(e) 2020. A comparison of p53 isoform profiles and apoptosis induced by camptothecin or a herbal khat extract (Catha edulis (vahl) forssk. ex endl.) in leukemic cell lines: Exploring cellular responses in therapy development. Cancers. 1-14.
  • Vis forfatter(e) 2020. A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation. Journal of Biological Chemistry. 15 sider.
  • Vis forfatter(e) 2020. Tyrosine kinase inhibitors and interferon‐α increase tunneling nanotube (TNT) formation and cell adhesion in chronic myeloid leukemia (CML) cell lines (. The FASEB Journal. 3774-3791.
  • Vis forfatter(e) 2019. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. Scientific Reports. 1-15.
  • Vis forfatter(e) 2019. Titrating complex mass cytometry panels. Cytometry Part A. 1-6.
  • Vis forfatter(e) 2019. Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. Cells.
  • Vis forfatter(e) 2019. Synthesis and investigation of Ag-NHC complexes with cytotoxic properties towards cell lines modelling acute myeloid leukemia .
  • Vis forfatter(e) 2019. Rethinking Gynecological High- Grade Serous Carcinoma. Portraying the p53 isoform landscape and development of a new preclinical for optical imaging in xenograft models.
  • Vis forfatter(e) 2019. Pretreatment of glioblastoma with bortezomib potentiates natural killer cell cytotoxicity through TRAIL/DR5 mediated apoptosis and prolongs animal survival. Cancers. 1-25.
  • Vis forfatter(e) 2019. Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 1729-1749.
  • Vis forfatter(e) 2019. Intracellular signaling in key pathways is induced by treatment with ultrasound and microbubbles in a leukemia cell line, but not in healthy peripheral blood mononuclear cells. Pharmaceutics. 1-17.
  • Vis forfatter(e) 2019. Influence of p53 isoform expression on survival in high-grade serous ovarian cancers. Scientific Reports. 1-11.
  • Vis forfatter(e) 2019. Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. Oncoimmunology. 1-13.
  • Vis forfatter(e) 2019. GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells. Haematologica.
  • Vis forfatter(e) 2019. Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: A case report. Journal of Medical Case Reports. 1-8.
  • Vis forfatter(e) 2019. Clinical trials of repurposing medicines in acute myeloid leukemia: Limitations and possibilities in the age of precision therapy. The Cancer Journal. 153-163.
  • Vis forfatter(e) 2019. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. British Journal of Cancer. 545-555.
  • Vis forfatter(e) 2018. Update on the randomised phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma. Annals of Oncology. viii452-viii452.
  • Vis forfatter(e) 2018. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison. Expert opinion on therapeutic targets. 639-653.
  • Vis forfatter(e) 2018. Single cell signalling and immune profiles in chronic myeloid leukaemia .
  • Vis forfatter(e) 2018. Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis. Biomarker Research.
  • Vis forfatter(e) 2018. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 1768-1777.
  • Vis forfatter(e) 2018. Maternal exposure to gasoline and exhaust increases the risk of childhood leukaemia in offspring - a prospective study in the Norwegian Mother and Child Cohort Study. British Journal of Cancer. 1028-1035.
  • Vis forfatter(e) 2018. Inhibition of tunneling nanotube (TNT) formation and Human T-cell leukemia virus type 1 (HTLV-1) transmission by cytarabine. Scientific Reports. 1-17.
  • Vis forfatter(e) 2018. High expression of the p53 isoform ? is associated with reduced progression-free survival in uterine serous carcinoma. BMC Cancer. 1-10.
  • Vis forfatter(e) 2018. Gene expression response in peripheral blood cells of petroleum workers exposed to sub-ppm benzene levels. International Journal of Environmental Research and Public Health (IJERPH). 1-18.
  • Vis forfatter(e) 2018. Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation. Case reports in hematology.
  • Vis forfatter(e) 2018. Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial. . Stem Cell Research & Therapy. 1-15.
  • Vis forfatter(e) 2017. development of novel Highly Specific FLT3 Targeted Inhibitors for Combination or Sequential Therapy of Acute Myeloid Leukemia.
  • Vis forfatter(e) 2017. combination of interferon-alpha and valproic acid in acute myeloid leukemia cells in vitro and in vivo.
  • Vis forfatter(e) 2017. a precision medicin platform for acute myeloid leukemia to help unraveling the molecular addictions of FLT3-ITD-driven AML.
  • Vis forfatter(e) 2017. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 1543-1554.
  • Vis forfatter(e) 2017. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-KB inhibition in acute myeloid leukemia (AML). OncoTarget. 7946-7963.
  • Vis forfatter(e) 2017. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood. 1636-1645.
  • Vis forfatter(e) 2017. Stroma-derived factors stimulate JAK/STAT signaling in AML cells resulring in resistance to BCL2 inhibitor Venetoclax.
  • Vis forfatter(e) 2017. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. Journal of Controlled Release. 70-80.
  • Vis forfatter(e) 2017. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica. 1361-1367.
  • Vis forfatter(e) 2017. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. Journal of Clinical Oncology. 175-184.
  • Vis forfatter(e) 2017. Proteomics and single cell immune and signaling profiling of myeloid leukemia.
  • Vis forfatter(e) 2017. Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. Journal of Proteomics. 32-41.
  • Vis forfatter(e) 2017. NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib. Leukemia. 2264-2267.
  • Vis forfatter(e) 2017. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood. 789-802.
  • Vis forfatter(e) 2017. In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL. Blood Cancer Journal. 4 sider.
  • Vis forfatter(e) 2017. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. Leukemia. 301-309.
  • Vis forfatter(e) 2017. Drug Repurposing for the Treatment of Acute Myeloid Leukemia. Frontiers in medicine.
  • Vis forfatter(e) 2017. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer. 1-13.
  • Vis forfatter(e) 2017. Biomarker Panels and Contemporary Practice in Clinical Trials of Targeted Therapy. 19 sider.
  • Vis forfatter(e) 2016. Ultrasound- and microbubble-enhanced chemotherapy for treating pancreatic cancer: a phase I clinical trial. Journal of the Acoustical Society of America. 2092-2092.
  • Vis forfatter(e) 2016. Ultrasound- and microbubble-enhanced chemotherapy for treating pancreatic cancer: A phase I clinical trial. Journal of the Acoustical Society of America.
  • Vis forfatter(e) 2016. Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. Journal of Clinical Oncology.
  • Vis forfatter(e) 2016. The HDACi panobinostat shows growth inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer. PLOS ONE.
  • Vis forfatter(e) 2016. Single-cell proteomics: Potential implications for cancer diagnostics. Expert Review of Molecular Diagnostics. 579-589.
  • Vis forfatter(e) 2016. Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells. Pharmacological Research. 216-227.
  • Vis forfatter(e) 2016. Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 1853-1860.
  • Vis forfatter(e) 2016. Leukocyte p38 and p53 proteins after environmental exposure; variation, associations and applicability.
  • Vis forfatter(e) 2016. Leukemic stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy. Clinical Cancer Research. 4030-4038.
  • Vis forfatter(e) 2016. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. OncoTarget. 8105-8118.
  • Vis forfatter(e) 2016. Elevated monocyte phosphorylated p38 in nearby employees after a chemical explosion. Scientific Reports.
  • Vis forfatter(e) 2016. Development of personalized molecular therapy for acute myeloid leukemia. Current Pharmaceutical Biotechnology. 20-29.
  • Vis forfatter(e) 2016. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death & Disease. 1-14.
  • Vis forfatter(e) 2016. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release. 172-181.
  • Vis forfatter(e) 2015. Sonoporation using Acoustic Cluster Therapy in combination With chemotherapy transiently reduces tumour volume. 1 sider.
  • Vis forfatter(e) 2015. Sonoporation using Acoustic Cluster Therapy in combination With chemotherapy transiently reduces tumour volume.
  • Vis forfatter(e) 2015. Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 mediate the cellular localization of nucleophosmin and its aml-associated mutants. ACS Chemical Biology. 855-863.
  • Vis forfatter(e) 2015. Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. OncoTarget. 2794-2811.
  • Vis forfatter(e) 2015. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia. 11-19.
  • Vis forfatter(e) 2015. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006). European Journal of Haematology. 243-250.
  • Vis forfatter(e) 2015. Bør hver kreftpasient bli et eget forskningsprosjekt? Aftenposten (morgenutg. : trykt utg.).
  • Vis forfatter(e) 2015. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunology and Immunotherapy. 337-347.
  • Vis forfatter(e) 2015. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunology and Immunotherapy. 337-347.
  • Vis forfatter(e) 2015. 4-alkylated silver-N-heterocyclic carbene (NHC) complexes with cytotoxic effects in leukemia cells. ChemMedChem. 1522-1527.
  • Vis forfatter(e) 2014. Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukemic compound PEP005 in primary AML cells. Oncoscience. 529-539.
  • Vis forfatter(e) 2014. Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions. Journal of Clinical Medicine.
  • Vis forfatter(e) 2014. Sonoporation: from the lab to human clinical trials. IEEE International Ultrasonics Symposium Proceedings. 846-849.
  • Vis forfatter(e) 2014. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft. Molecular Imaging and Biology. 53-62.
  • Vis forfatter(e) 2014. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell. 431-446.
  • Vis forfatter(e) 2014. Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines. Proteomics. 1971-1976.
  • Vis forfatter(e) 2014. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia. 1738-1742.
  • Vis forfatter(e) 2014. Mot en mer spesifikk kreftbehandling? :. Tidsskrift for Den norske legeforening. 1017.
  • Vis forfatter(e) 2014. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Molecular Cancer.
  • Vis forfatter(e) 2014. First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. PLOS ONE.
  • Vis forfatter(e) 2014. Evaluation of the effects of clinical diagnostic ultrasound in combination with ultrasound contrast agents on cell stress: Single cell analysis of intracellular phospho-signaling pathways in blood cancer cells and normal blood leukocytes. IEEE International Ultrasonics Symposium Proceedings. 1186-1190.
  • Vis forfatter(e) 2014. Deficient phosphorylation of stat-1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta. PLOS ONE.
  • Vis forfatter(e) 2014. Cell-to-Cell Communication in Acute Myeloid Leukemia by Tunneling Nanotubes.
  • Vis forfatter(e) 2014. A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. Leukemia and Lymphoma. 2114-2119.
  • Vis forfatter(e) 2013. cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases. International Journal of Oncology. 1815-1821.
  • Vis forfatter(e) 2013. Ultrasound-assisted treatment of an inoperable pancreatic cancer. 4 sider.
  • Vis forfatter(e) 2013. Ultrasound combined with microbubbles modulates signal transduction pathways in blood cells. 2 sider.
  • Vis forfatter(e) 2013. Ultrasound and microbubble enhanced therapy of orthotopic human pancreatic cancer in mice. 3 sider.
  • Vis forfatter(e) 2013. Tunneling nanotube (TNT) formation is independent of p53 expression. Cell Death and Differentiation. 1124-1124.
  • Vis forfatter(e) 2013. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clinical Epigenetics.
  • Vis forfatter(e) 2013. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions? Current Cancer Drug Targets. 30-47.
  • Vis forfatter(e) 2013. Phosphoprotein signaling in acute myeloid leukemia.
  • Vis forfatter(e) 2013. Panobinostat / carboplatin delay postsurgical relapse of ovarian carcinomas in an orthotopic mouse model.
  • Vis forfatter(e) 2013. PANOBINOSTAT / CARBOPLATIN DELAY POSTSURGICAL RELAPSE OF OVARIAN CARCINOMA IN AN ORTHOTOPIC MOUSE MODEL. International Journal of Gynecological Cancer. 1 sider.
  • Vis forfatter(e) 2013. Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer. Cancer Research. 1276-1286.
  • Vis forfatter(e) 2013. Målrettet behandling av akutt myelogen leukemi - hemmere mot FLT3 og andre kinaser viser vei. Best Practice.
  • Vis forfatter(e) 2013. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. E34-E42.
  • Vis forfatter(e) 2013. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discovery. 1416-1429.
  • Vis forfatter(e) 2013. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opinion on Investigational Drugs. 551-563.
  • Vis forfatter(e) 2013. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia. 1520-1526.
  • Vis forfatter(e) 2013. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clinical Epigenetics.
  • Vis forfatter(e) 2013. Histone deacetylase inhibisjon i kombinasjon med platinum i en klinisk relevant ortotopisk musemodel for ovarialcancer.
  • Vis forfatter(e) 2013. Gel2DE-A software tool for correlation analysis of 2D gel electrophoresis data. BMC Bioinformatics. 5 sider.
  • Vis forfatter(e) 2013. Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen. BMC Cancer.
  • Vis forfatter(e) 2013. Expression of TP53 isoforms p53 beta or p53 gamma enhances chemosensitivity in TP53(null) cell lines. PLOS ONE. 11 sider.
  • Vis forfatter(e) 2013. Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine. BMC Pharmacology & Toxicology. 13 sider.
  • Vis forfatter(e) 2013. Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death & Disease.
  • Vis forfatter(e) 2013. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1-and LAGE-1-positive tumors. Cancer Immunology and Immunotherapy. 773-785.
  • Vis forfatter(e) 2012. Volume visualization for exploration of population trends in two-dimensional gel electrophoresis protein data. Computer-Based Medical Systems. 1-6.
  • Vis forfatter(e) 2012. Targeting of polo-like kinases and their cross talk with Aurora kinases - possible therapeutic strategies in human acute myeloid leukemia? Expert Opinion on Investigational Drugs. 587-603.
  • Vis forfatter(e) 2012. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 910-917.
  • Vis forfatter(e) 2012. Single cell pStat1 activation, a promising biomarker to evaluate neutralizing antibody effects in interferon-beta treated multiple sclerosis patients. Journal of Neuroimmunology. 18-19.
  • Vis forfatter(e) 2012. Microbubbles and cell interactions. 2 sider.
  • Vis forfatter(e) 2012. Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. Cell Death and Differentiation. 1381-1389.
  • Vis forfatter(e) 2012. Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting. Journal of Proteomics. 69-78.
  • Vis forfatter(e) 2012. Investigation of therapy resistance mechanisms in myeloid leukemia by protein profiling of bone marrow extracellular fluid. Espert Review of Proteomics. 595-598.
  • Vis forfatter(e) 2012. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. Multiple Sclerosis. 1116-1124.
  • Vis forfatter(e) 2012. Human cells and the Norwegian Health Research Act. Tidsskrift for Den norske legeforening. 540-542.
  • Vis forfatter(e) 2012. Flow cytometic characterization and sorting of ultrasound contrast agents. 13 sider.
  • Vis forfatter(e) 2012. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention. British Journal of Haematology. 468-480.
  • Vis forfatter(e) 2012. Establishment of a bioluminescence orthotopic mouse model of ovarian carcinoma: Analysis of tumor growth and response to therapy. Acta Obstetricia et Gynecologica Scandinavica. 16-17.
  • Vis forfatter(e) 2012. Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. Cell Biology and Toxicology. 201-212.
  • Vis forfatter(e) 2012. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. American Journal of Hematology. 368-376.
  • Vis forfatter(e) 2012. Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. European Journal of Clinical Investigation. 1016-1026.
  • Vis forfatter(e) 2012. Deformation of acute myeloid leukaemia cells in micro-constriction array; a novel tool to study cell stress signalling.
  • Vis forfatter(e) 2012. Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLOS ONE.
  • Vis forfatter(e) 2012. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 1533-1545.
  • Vis forfatter(e) 2012. A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline. Blood. 2 sider.
  • Vis forfatter(e) 2011. Untangling the intracellular signalling network in cancer - a strategy for data integration in acute myeloid leukemia. Journal of Proteomics. 269-281.
  • Vis forfatter(e) 2011. Stratification of pediatric acute myeloid leukemia through cancer cell gene-expression profiling. Expert Review of Anticancer Therapy. 355-357.
  • Vis forfatter(e) 2011. Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. Blood Cancer Journal.
  • Vis forfatter(e) 2011. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncology Reports. 1549-1556.
  • Vis forfatter(e) 2011. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Clinical and Experimental Metastasis. 234-235.
  • Vis forfatter(e) 2010. Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB. Leukemia Research. 77-84.
  • Vis forfatter(e) 2010. OXYGEN LEVELS INFLUENCE THE CYTOKINE RELEASE PROFILE OF AML CELLS. Experimental Hematology. S119-S119.
  • Vis forfatter(e) 2010. Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia. Nutrition and Cancer. 574-583.
  • Vis forfatter(e) 2010. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunology.
  • Vis forfatter(e) 2010. Hypoxia increases HIF-1 alpha expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. European Cytokine Network. 154-164.
  • Vis forfatter(e) 2010. Combined epigenetic and signal transduction therapy modulate specific signal transduction patterns in acute myeloid leukemia. Haematologica. 510-510.
  • Vis forfatter(e) 2010. Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia - a report of five cases. Hematology. 338-343.
  • Vis forfatter(e) 2010. Clinical proteomics of myeloid leukemia. Genome Medicine.
  • Vis forfatter(e) 2010. Cellular stress induced by resazurin leads to autophagy and cell death via production of reactive oxygen species and mitochondrial impairment. Journal of Cellular Biochemistry. 574-584.
  • Vis forfatter(e) 2010. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America. 1124-1129.
  • Vis forfatter(e) 2010. Access to the spleen microenvironment through lymph shows local cytokine production, increased cell flux, and altered signaling of immune cells during lipopolysaccharide-induced acute inflammation. Journal of Immunology. 4547-4556.
  • Vis forfatter(e) 2009. The protein kinase C agonist PEP005 increases NF-kB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. British Journal of Haematology. 761-774.
  • Vis forfatter(e) 2009. Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opinion on Investigational Drugs. 433-455.
  • Vis forfatter(e) 2009. TARGETING THE TUMOR STROMA: A NOVEL THERAPEUTIC STRATEGY BASED ON SEPARATE ANALYSIS OF THE MALIGNANT AND STROMAL CELL COMPARTMENTS IN BRAIN TUMORS. Neuro-Oncology. 965-965.
  • Vis forfatter(e) 2009. Signalhemmere. 24 sider.
  • Vis forfatter(e) 2009. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. British Journal of Haematology. 53-68.
  • Vis forfatter(e) 2009. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 53-68.
  • Vis forfatter(e) 2009. Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia. Critical reviews in oncogenesis. 1-41.
  • Vis forfatter(e) 2009. Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells. Leukemia Research. 276-287.
  • Vis forfatter(e) 2009. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumour model. Neoplasia. 812-822.
  • Vis forfatter(e) 2009. Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer.
  • Vis forfatter(e) 2009. Er høyt hemoglobinnivå farlig? Tidsskrift for Den norske legeforening. 1881-1882.
  • Vis forfatter(e) 2009. Early loss of mitochondrial inner transmembrane potential in khat-induced cell death of primary normal human oral cells. Toxicology. 108-116.
  • Vis forfatter(e) 2009. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. European Journal of Pharmacology. 6-22.
  • Vis forfatter(e) 2009. Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. Molecular Cancer.
  • Vis forfatter(e) 2009. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leukemia Research. 779-787.
  • Vis forfatter(e) 2008. Review: genetic models of acute myeloid leukaemia. Oncogene. 3765-3779.
  • Vis forfatter(e) 2008. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia. 287-293.
  • Vis forfatter(e) 2008. Khat induces G1-phase arrest and increased expression of stress-sensitive p53 and p16 proteins in normal human oral keratinocytes and fibroblasts. European Journal of Oral Sciences. 23-30.
  • Vis forfatter(e) 2008. Interferon-beta signal transduction, multiple sclerosis and auto-antibodies. Journal of Neuroimmunology. 134-135.
  • Vis forfatter(e) 2008. In vivo biological effects of ATRA in the treatment of AML. Expert Opinion on Investigational Drugs. 1623-1633.
  • Vis forfatter(e) 2008. FLT3 internal tandem duplication involving its libiquitin dependent endocytosis motif suspend modulation by HDM2 and are associated with inferior survival in AML. Haematologica. 10-10.
  • Vis forfatter(e) 2008. Evaluation of combinational therapy of MDM2-antagonist nutlin-3 and HDAC-inhibitor valproic acid in acute myeloid leukemia in vitro and in vivo. Blood. 1024-1024.
  • Vis forfatter(e) 2008. Erythropoietin a safe bet in haemorrhagic shock? Acta Anaesthesiologica Scandinavica. 585-586.
  • Vis forfatter(e) 2008. Effects of benzene on human hematopoiesis. The Open Hematology Journal. 87-102.
  • Vis forfatter(e) 2008. Comprehensive Analysis of Gene Function: RNA interference and Chemical Genomics. 13 sider.
  • Vis forfatter(e) 2008. Anticancer Immunotherapy in Combination with Proapoptotic Therapy. Current Cancer Drug Targets. 666-675.
  • Vis forfatter(e) 2008. Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood. 2866-2877.
  • Vis forfatter(e) 2007. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology. 814-828.
  • Vis forfatter(e) 2007. Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. Expert opinion on therapeutic targets. 1055-1069.
  • Vis forfatter(e) 2007. T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005. Cancer Immunology and Immunotherapy. 013-925.
  • Vis forfatter(e) 2007. Synergistic anti-leukemic effect of protein kinase a activator and PPAR7agonist is independent of Bcl-2 status. Blood. 117B-117B.
  • Vis forfatter(e) 2007. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 332-341.
  • Vis forfatter(e) 2007. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Molecular Cancer.
  • Vis forfatter(e) 2007. New lessons from an "old" drug: A proteomic study of anthracycline-induced apoptosis in acute myelogenous leukemia.
  • Vis forfatter(e) 2007. Linking susceptibility to histone deactylase inhibitors and basal gene expression profiles in acute myeloid leukaemia. Experimental Hematology. 77-77.
  • Vis forfatter(e) 2007. LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Molecular Cancer.
  • Vis forfatter(e) 2007. In vivo optical imaging of p53 specific targeted therapy in Acute Myeloid Leukaemia.
  • Vis forfatter(e) 2007. In vivo optical Imaging of acute myeloid leukemia by green fluorescent protein: Time-domain autofluorescence decoupling, fluorophore quantification, and localization. Molecular Imaging. 193-204.
  • Vis forfatter(e) 2007. Immunological aspects of acute myelogenous leukemia.
  • Vis forfatter(e) 2007. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. Current Pharmaceutical Biotechnology. 388-400.
  • Vis forfatter(e) 2007. Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in Acute Myeloid Leukemia. Current Pharmaceutical Biotechnology. 344-354.
  • Vis forfatter(e) 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukamia cells indentify patient subgroups that differ susceptibility to histone deactylase inhibitors. International Journal of Oncology. 1529-1538.
  • Vis forfatter(e) 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in the susceptibility to histone deacetylase inhibitors. Haematologica. 112-112.
  • Vis forfatter(e) 2007. Flt3 receptor tyrosine kinase in AML and its modulation of the p53/Hdm2/Bcl-2 pathway.
  • Vis forfatter(e) 2007. Flt3 mutations in proximity to an ubiquitin dependent endocytosis motif suspend its Hdm2 modulation. Blood. 148B-148B.
  • Vis forfatter(e) 2007. Flt3 Y591 duplication and Bc1-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood. 2589-2596.
  • Vis forfatter(e) 2007. Flt3 Mutations in Proximity to an Ubiquitin Dependent Endocytosis Motif Suspend Its Hdm2 Modulation.
  • Vis forfatter(e) 2007. Effects of interferon gamma on native human acute myelogenous leukaemia cells. Cancer Immunology and Immunotherapy. 13-24.
  • Vis forfatter(e) 2007. Early protein and gene modulation in response to induction chemotherapy of acute myeloid leukemia.
  • Vis forfatter(e) 2007. Early gene expression signature of chemotherapy treated acute myeloid leukemia in vivo.
  • Vis forfatter(e) 2007. Early gene expression of acute myeloid leukemia in response to chemotherapy. Expert Review of Anticancer Therapy. 741-751.
  • Vis forfatter(e) 2007. Early Protein and Gene Modulation in Response to Induction Chemotherapy of Acute Myeloid Leukemia.
  • Vis forfatter(e) 2007. Discrimination and quantification of spectrally similar near-infrared probes by time-domain (TD) optical imaging in acute myeloid leukemia mouse models. Blood. 147B-148B.
  • Vis forfatter(e) 2007. Discrimination and Quantification of Spectrally Similar Near-Infrared Probes by Time-Domain (TD) Optical Imaging in AML models.
  • Vis forfatter(e) 2007. Development of a near infrared reporter system for in vivo imaging.
  • Vis forfatter(e) 2007. Development and evaluation of labeled antibodies as optical contrast reagents in acute myeloid leukemia (AML).
  • Vis forfatter(e) 2007. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. European Journal of Haematology. 210-225.
  • Vis forfatter(e) 2007. Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Analytical Biochemistry. 46-58.
  • Vis forfatter(e) 2007. Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex. Hematology. 199-207.
  • Vis forfatter(e) 2007. Bcl-2 antisense in the treatment of human malignancies: A delusion in targeted therapy. Current Pharmaceutical Biotechnology. 373-381.
  • Vis forfatter(e) 2007. Anti-tumor activity of immunoproteasome selective inhibitors. Blood. 477A-478A.
  • Vis forfatter(e) 2007. Anti-Tumor Activity of Immunoproteasome Selective Inhibitors.
  • Vis forfatter(e) 2006. p53 protein biosignatures in acute myeloid leukemia.
  • Vis forfatter(e) 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. International Journal of Oncology. 1065-1080.
  • Vis forfatter(e) 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation.
  • Vis forfatter(e) 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. NBS-nytt. 106.
  • Vis forfatter(e) 2006. Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia. Acta Oncologica. 346-349.
  • Vis forfatter(e) 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy. International Journal of Molecular Medicine. S65.
  • Vis forfatter(e) 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy.
  • Vis forfatter(e) 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy.
  • Vis forfatter(e) 2006. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2 : Bax ratio and low levels of heat shock protein 70 and 90. Leukemia Research. 1531-1540.
  • Vis forfatter(e) 2006. Proteomics of p53 in diagnostics and therapy of acute myeloid leukemia. Current Pharmaceutical Biotechnology. 199-207.
  • Vis forfatter(e) 2006. Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies. Current Pharmaceutical Biotechnology. 185-198.
  • Vis forfatter(e) 2006. Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). Current Pharmaceutical Biotechnology. 159-170.
  • Vis forfatter(e) 2006. Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). Current Pharmaceutical Biotechnology. 159-170.
  • Vis forfatter(e) 2006. Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert opinion on therapeutic targets. 51-68.
  • Vis forfatter(e) 2006. Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia? Cancer Immunology and Immunotherapy. 221-228.
  • Vis forfatter(e) 2006. Immunotherapy in chronic lymphocytic leukemia. Cancer Immunology and Immunotherapy. 185-187.
  • Vis forfatter(e) 2006. Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. BMC Bioinformatics. 198.
  • Vis forfatter(e) 2006. CaM-kinasell-dependent commitment to microcystin-induced apoptosis is coupled to cell budding, but not to shrinkage or chromatin hypercondensation. Cell Death and Differentiation. 1191-1202.
  • Vis forfatter(e) 2006. Adaptive contrast enhancement of two-dimensional electrophoretic protein gel images facilitates visualization, orientation and alignment. Electrophoresis. 4086-4095.
  • Vis forfatter(e) 2006. Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report. Leukemia. 734-736.
  • Vis forfatter(e) 2006. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clinical Cancer Research. 3985-3992.
  • Vis forfatter(e) 2005. The role of Bcl-2 in apoptosis induced by khat (Catha edulis) in acute myeloid leukemia cell lines. Blood. 195b-195b.
  • Vis forfatter(e) 2005. Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy. Current Drug Targets. 631-646.
  • Vis forfatter(e) 2005. Proteomics in acute myelogenous leukaemia (AML): Methodological strategies-and identification of protein targets for novel antileukaemic therapy. Current Drug Targets. 631-646.
  • Vis forfatter(e) 2005. Khat- and cathionine-induced apoptosis is modulated by Bcl-2 protein expression.
  • Vis forfatter(e) 2005. Antiangiogenic therapy in acute myelogenous leukemia: Targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Current Cancer Drug Targets. 229-248.

Se fullstendig oversikt over publikasjoner i CRIStin.

1. Omsland M, Vibeke Andresen V, Gullaksen SE, Ayuda-Durán P, Popa M, Hovland R, Brendehaug A, Enserink J, McCormack E, Gjertsen BT. Interferon alpha and tyrosine kinase inhibitors increase tunneling nanotubes (TNT) formation and cell adhesion in chronic myeloid leukemia (CML) cell lines. FASEB J. 2020 34(3):3773-3791. Citations: 3. IF 5.191. ••Impact: The first report on upregulation of TNT by kinase inhibitors and indicate that the old anti-leukemic interferon-alpha act share the same mechanism as kinase inhibitors. The effect of kinase inhibitor on TNT is an example of functional regulation by small molecules.

 

2.  Gullaksen SE, Skavland J, …, Gjertsen BT. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukaemia treated with nilotinib. Haematologica 2017; 102:1361-1367. Citations: 13. IF 5.814. •••Impact: This paper introduces mass cytometry panel as a core technology for single cell monitoring in clinical trials. Prognostication based on single cell analysis at 7 days indicate molecular response (tumour load) at 18 months on targeted therapy that predispose to cardiovascular disease.

 

3. Engen C, Hellesøy M, Grob T, Löwenberg B, Valk PJM, Gjertsen BT. Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis. Mol Oncol. 2021 Jun 8. doi: 10.1002/1878-0261.13035. Citations: 0. IF 6.603. ••Impact: Prognostication based on FLT3 genetics seems only to be valid for females. Leukaemia cell samples are distinct in females and males in terms of gene expression and ex vivo drug sensitivity, in addition to the previously known sex depended mutational profile of leukaemia.

 

4. Engen C, Hellesøy M, Grob T, Hinai AA, Brendehaug A, Wergeland L, Bedringaas SL, Hovland R, Valk PJM, Gjertsen BT. FLT3-ITD mutations in acute myeloid leukaemia - Molecular characteristics, distribution and numerical variation. Mol Oncol. 2021 Apr 5. doi: 10.1002/1878-0261.12961. Citations: 0. IF 6.603. •Impact: This report demonstrates the heterogeneity of FLT3 mutations in AML, and raise a question about more accurate tools for therapy monitoring for varying cell populations in the same patient.

 

5. Forthun RB, Aasebø E, Rasinger JD, Bedringaas SL, Berven F, Selheim F, Bruserud Ø, Gjertsen BT. Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. J Proteomics. 2018 Feb 20;173:32-41. Citations: 7. IF 3.537. ••Impact: Underpinning data on signaling networks affected by the phenotypes and genetics in AML.

 

6. McCormack E, Mujic M, Osdal T, Bruserud Ø, Gjertsen BT. Multiplexed monoclonal antibodies: A new strategy in preclinical time domain imaging of acute myeloid leukemia. Citations: 15. IF 9.060. Blood. 2013;121:e34-42. Impact: outline in vivo multiplexing imaging in leukemia. •••Impact: Seminal paper that point in the direction of multiplex analysis in medical imaging.

             

7. Sulen A, Lygre SH, Hjelle SM, Hollund BE, Gjertsen BT. Elevated monocyte phosphorylated p38 in nearby employees after a chemical explosion. Sci Rep. 2016 Jul 6;6:29060. Citations: 1. IF 4.259. ••Impact: Demonstrate that single cell signaling profiling in a cross-sectional healthy survey can be used to examine exposure to smoke and correlate with occupational activity of exposure.

 

8. McCormack E, Haaland I, …, Gjertsen BT. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 2012 May;26(5):910-7. Citations: 63. IF 11.528. •Impact: Developing low toxicity combination and use of protein biomarkers to monitor therapy response.  

 

9. Andresen V, …, Gjertsen BT. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death Dis. 2016 Dec 1;7(12):e2497. Citations: 8. IF 5.965. •Impact: Targeted therapy concept that point in the direction of functional diagnostics.

 

10. Ånensen N, ..., Gjertsen BT. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 2012;31(12):1533-45. Citations: 44. IF 5.965. •••Impact: First report on protein p53 isoform analysis in prognostication demonstrating consistency between p53 isoform profiles, genomics, therapy response and survival in AML.  

Twitter